BARCELONA, Feb 28 (Reuters) - Spanish pharmaceutical company Grifols' (GRLS.MC) shares fell around 10% in afternoon trading after its 2023 outlook disappointed analysts, who were looking for a better recovery in margins. Grifols reported on Tuesday that net profit rose 10% to 208 million euros ($220.19 million). Total revenues rose 23% to 6 billion euros ($6.38 billion), with over half generated in the United States and Canada. JPMorgan said the progress on EBITDA margin recovery in 2023 may be a little slower than the market had hoped. Grifols announced earlier this month it would lay off 8.5% of its workforce seeking annual savings of around 400 million euros.

---